• 作者：José ; Miguel Senabre-Gallego^a ; ^{senabre@hotmail.es} ; José ; Rosas-Gó ; mez de Salazar^a ; Gregorio Santos-Soler^a ; Carlos Santos-Ram&#237 ; rez^b ; Mabel Sá ; nchez-Barrioluengo^c ; Esteban Salas-Heredia^a ; Xavier Barber-Vallé ; s^d ; Catalina Cano-Pé ; rez^e ; Nú ; ria Llah&#237 ; -Vidal^e ; Rosa Riestra-Juá ; n^e
• 关键词：Acontecimiento adverso ; Artritis ; Discontinuació ; n ; Etanercept ; Supervivencia ; Terapia bioló ; gica
• 刊名：Reumatolog铆a Cl铆nica
• 出版年：2011
• 期刊代码：pca303_1699258X
• 类别：med
• 出版时间：November-December 2011
• 卷：7
• 期：6
• 页码：385-388
• 文件大小：154 K

Objective

To evaluate the duration of etanercept (ETN) treatment and motives for discontinuation in our local cohort of patients with rheumatic pathology and compare them to the group with other biological treatments.

Patients and methods

Prospective observational cohort study. Disease diagnosis, start and end date and motive for discontinuation were recorded. Survival estimation was explored using Kaplan-Meier analysis with remaining patients censored at 1-year, 2-years and 5-years follow-up.

Results

Ninety-two (45%) out of 205 patients started ETN treatment. Disease diagnoses recorded were: 48%rheumatoid arthritis, 33%ankylosing spondylitis, 11%psoriatic arthritis, 8%others (juvenile idiopathic arthritis, inflammatory bowel disease related spondylitis, SAPHO syndrome). 52%of patients are still on the drug. The motives for discontinuation were: inefficacy (65%), adverse events (33%) and lack of compliance (2%). Two patients discontinued ETN due to prolonged disease control. Adverse events were: infection (4 patients), post-injection skin reaction (3), uveitis (3), neoplasia (2) and others (3). Using a Kaplan鈥揗eier analysis, at 1-year 64%(CI_95% 54-74) of patients with ETN treatment had not experienced treatment failure, at 2-years, 59%(48-69) and at 5-years, 43%(30-52). With the rest of biologicals estimated survival was 61%(51-68), 47,5%(40-55) and 23%(10,5-32) respectively. Statistical analysis revealed significant differences (log-rank: P=.024; Breslow: P=.068; Tarone-Ware: P = .040).

Conclusions

In our cohort of patients treated with ETN the estimated survival was better than patients treated with other biological drugs at 1-year, 2-years and 5-years.